Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab in Moderate to Severe Rheumatoid Arthritis
NCT01373151Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Jun 2011
- Primary completion
- Sep 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 2 trial of clazakizumab in rheumatoid arthritis (RA), sponsored by CSL Limited. Started Jun 2011; status: completed.
02
Drugs
clazakizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01373151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01373151.